These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 23560534

  • 1. Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
    Barrio S, Gallardo M, Arenas A, Ayala R, Rapado I, Rueda D, Jiménez-Ubieto A, Albizua E, Burgaleta C, Gilsanz F, Martinez-Lopez J.
    Br J Haematol; 2013 Jun; 161(5):667-676. PubMed ID: 23560534
    [Abstract] [Full Text] [Related]

  • 2. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L, Lambert QT, Pradhan A, Griner LN, Huszar D, Reuther GW.
    Oncotarget; 2015 Nov 24; 6(37):40141-57. PubMed ID: 26472029
    [Abstract] [Full Text] [Related]

  • 3. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
    Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S.
    Blood; 2010 Apr 15; 115(15):3109-17. PubMed ID: 20130243
    [Abstract] [Full Text] [Related]

  • 4. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
    Nagao T, Kurosu T, Umezawa Y, Nogami A, Oshikawa G, Tohda S, Yamamoto M, Miura O.
    PLoS One; 2014 Apr 15; 9(1):e84746. PubMed ID: 24404189
    [Abstract] [Full Text] [Related]

  • 5. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
    de Melo Campos P, Machado-Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, da Silva Souza Duarte A, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Olalla Saad ST, Traina F.
    Oncotarget; 2016 Feb 09; 7(6):6948-59. PubMed ID: 26755644
    [Abstract] [Full Text] [Related]

  • 6. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
    Hao X, Xing W, Yuan J, Wang Y, Bai J, Bai J, Zhou Y.
    Invest New Drugs; 2020 Jun 09; 38(3):610-620. PubMed ID: 31227936
    [Abstract] [Full Text] [Related]

  • 7. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
    Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A, Vannucchi AM, Associazione Italiana per la Ricerca sul Cancro AGIMM Gruppo Italiano Malattie Mieloproliferative.
    PLoS One; 2013 Jun 09; 8(1):e54826. PubMed ID: 23382981
    [Abstract] [Full Text] [Related]

  • 8. Novel therapeutics in myeloproliferative neoplasms.
    Venugopal S, Mascarenhas J.
    J Hematol Oncol; 2020 Dec 02; 13(1):162. PubMed ID: 33267911
    [Abstract] [Full Text] [Related]

  • 9. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D, Ghazanfari R, Li H, Lim HC, Scheding S.
    Eur J Haematol; 2018 Jul 02; 101(1):57-67. PubMed ID: 29645296
    [Abstract] [Full Text] [Related]

  • 10. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
    Bose P, Verstovsek S.
    Expert Opin Investig Drugs; 2016 Dec 02; 25(12):1393-1403. PubMed ID: 27756180
    [Abstract] [Full Text] [Related]

  • 11. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
    Mazzacurati L, Collins RJ, Pandey G, Lambert-Showers QT, Amin NE, Zhang L, Stubbs MC, Epling-Burnette PK, Koblish HK, Reuther GW.
    Blood Adv; 2019 Nov 26; 3(22):3503-3514. PubMed ID: 31725895
    [Abstract] [Full Text] [Related]

  • 12. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.
    Choong ML, Pecquet C, Pendharkar V, Diaconu CC, Yong JW, Tai SJ, Wang SF, Defour JP, Sangthongpitag K, Villeval JL, Vainchenker W, Constantinescu SN, Lee MA.
    J Cell Mol Med; 2013 Nov 26; 17(11):1397-409. PubMed ID: 24251790
    [Abstract] [Full Text] [Related]

  • 13. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
    Griesshammer M, Sadjadian P.
    Expert Opin Pharmacother; 2017 Dec 26; 18(18):1929-1938. PubMed ID: 29134817
    [Abstract] [Full Text] [Related]

  • 14. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
    Bose P, Verstovsek S.
    Blood; 2017 Jul 13; 130(2):115-125. PubMed ID: 28500170
    [Abstract] [Full Text] [Related]

  • 15. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
    Pardanani A, Tefferi A.
    Leuk Lymphoma; 2014 Dec 13; 55(12):2706-11. PubMed ID: 25520049
    [Abstract] [Full Text] [Related]

  • 16. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms.
    Hu M, Xu C, Yang C, Zuo H, Chen C, Zhang D, Shi G, Wang W, Shi J, Zhang T.
    J Exp Clin Cancer Res; 2019 Feb 04; 38(1):49. PubMed ID: 30717771
    [Abstract] [Full Text] [Related]

  • 17. SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.
    Pandey G, Mazzacurati L, Rowsell TM, Horvat NP, Amin NE, Zhang G, Akuffo AA, Colin-Leitzinger CM, Haura EB, Kuykendall AT, Zhang L, Epling-Burnette PK, Reuther GW.
    Am J Hematol; 2024 Jun 04; 99(6):1040-1055. PubMed ID: 38440831
    [Abstract] [Full Text] [Related]

  • 18. Dasatinib inhibits progenitor cell proliferation from polycythaemia vera.
    Wappl M, Jaeger E, Streubel B, Gisslinger H, Schwarzinger I, Valent P, Oehler L.
    Eur J Clin Invest; 2008 Aug 04; 38(8):578-84. PubMed ID: 18717827
    [Abstract] [Full Text] [Related]

  • 19. Effects of Ruxolitinib on Immune Checkpoint Molecule Expression in JAK2 V617F-Positive Cells.
    Fu J, Cheng Z, Zhang L, Wen X, Hao J.
    Clin Lab; 2024 Oct 01; 70(10):. PubMed ID: 39382932
    [Abstract] [Full Text] [Related]

  • 20. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
    Treliński J, Robak T.
    Curr Med Chem; 2013 Oct 01; 20(9):1147-61. PubMed ID: 23317159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.